Curative Biotechnology, Inc. is a biomedical company that focuses on developing pipeline candidates for infectious diseases, oncology, and degenerative eye diseases. The company's pipeline candidates include novel immune therapy for rabies and vaccines, humanized CD56 monoclonal antibody for inhibiting tumor growth and migration, and Metformin Reformulation for the treatment of degenerative eye disease. Curative Biotechnology also has a licensing and co-development agreement with Mid-Atlantic BioTherapeutics, Inc. to develop IMT504 to treat late-stage rabies and COVID-19 vaccine.